List of Excipients in Branded Drug AMARYL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	AMARYL	glimepiride	0039-0221	CELLULOSE, MICROCRYSTALLINE
Sanofi-Aventis US LLC	AMARYL	glimepiride	0039-0221	FERRIC OXIDE RED
Sanofi-Aventis US LLC	AMARYL	glimepiride	0039-0221	LACTOSE
Sanofi-Aventis US LLC	AMARYL	glimepiride	0039-0221	MAGNESIUM STEARATE
Sanofi-Aventis US LLC	AMARYL	glimepiride	0039-0221	POVIDONE
Sanofi-Aventis US LLC	AMARYL	glimepiride	0039-0221	SODIUM STARCH GLYCOLATE TYPE A CORN

Last updated: August 10, 2026

Amaryl (glimepiride) is an immediate-release sulfonylurea with an expired core exclusivity position and broad generic competition. Its commercial opportunity is not in replicating the branded tablet alone. The stronger opportunities are low-cost generic manufacturing, excipient optimization for content uniformity and dissolution, orally disintegrating or mini-tablet formats, and fixed-dose combinations with metformin. The principal technical constraint is the very low active dose, which increases blend-uniformity and segregation risk.

Amaryl Glimepiride Excipient Strategy, Patent Position, and Commercial Opportunities

What is Amaryl and how is it formulated?

Amaryl is the branded oral antidiabetic product containing glimepiride. Glimepiride is a third-generation sulfonylurea indicated, together with diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.[1]

The U.S. product is an immediate-release tablet available in 1 mg, 2 mg and 4 mg strengths. The formulation is designed for once-daily oral administration and does not rely on a controlled-release delivery system.[1]

The U.S. prescribing information identifies the following core inactive ingredients:

Excipient	Primary function
Lactose monohydrate	Diluent and tablet bulk
Microcrystalline cellulose	Diluent, dry binder and compression aid
Povidone	Binder
Sodium starch glycolate	Superdisintegrant
Magnesium stearate	Lubricant
Strength-specific colorants	Product identification and dose differentiation

The exact colorant system can vary by strength and market. Regulatory filings and local labels should be reviewed before treating the U.S. composition as representative of every Amaryl market.

The formulation is conventional, immediate-release and relatively accessible to generic developers. Its principal development challenge is not complex drug delivery. It is reliable distribution of a low quantity of glimepiride throughout the tablet blend.

What excipient strategy does Amaryl use?

Amaryl uses a conventional direct-compression or closely related immediate-release excipient platform built around lactose, microcrystalline cellulose, povidone, sodium starch glycolate and magnesium stearate.

Lactose and microcrystalline cellulose

The lactose-cellulose combination provides tablet mass and supports manufacturability across the 1 mg, 2 mg and 4 mg strengths. The 1 mg tablet contains a particularly small active load relative to total tablet weight. That ratio creates a greater risk of content-uniformity failure if glimepiride is not adequately dispersed.

Microcrystalline cellulose contributes compactibility and helps maintain mechanical strength at a tablet size acceptable for chronic use. The combination also gives manufacturers flexibility to adjust compression force, disintegration time and friability without changing the active ingredient.

Povidone

Povidone improves interparticle binding and helps prevent weak tablets when the formulation contains a high proportion of diluent. Its use is conventional, but concentration and grade can influence granule strength, dissolution and residual moisture.

For a generic developer, the key question is whether povidone is needed at the same level as in the reference product. A lower binder concentration may improve disintegration, while a higher concentration may reduce friability but delay drug release.

Sodium starch glycolate

Sodium starch glycolate provides rapid tablet breakup after ingestion. Immediate release is commercially important because glimepiride is generally dosed once daily and the reference product is not positioned as a modified-release formulation.

Excessive superdisintegrant levels can increase swelling, alter dissolution profiles or complicate blend flow. The practical objective is rapid and reproducible disintegration rather than the highest possible concentration.

Magnesium stearate

Magnesium stearate improves ejection and prevents sticking during compression. Over-lubrication can reduce tablet tensile strength and slow wetting or dissolution. Mixing time, lubricant particle size and shear exposure are therefore important process variables.

For glimepiride, dissolution sensitivity may be more commercially important than the low absolute cost of magnesium stearate. A generic product can fail comparative dissolution even when its assay and content uniformity are acceptable.

What are the main technical risks in an Amaryl generic?

The most significant technical risks are low-dose uniformity, blend segregation, dissolution variation and scale-up reproducibility.

Low-dose content uniformity

Glimepiride is present at 1 mg, 2 mg or 4 mg per tablet. The active represents a small fraction of the finished dosage unit. Direct blending can produce unacceptable potency variation if particle-size distributions, density and flow properties are poorly controlled.

Development teams commonly address this risk through:

• geometric dilution;
• pre-blending or ordered mixing;
• particle-size control;
• wet granulation;
• dry granulation;
• carrier-based premixes;
• low-shear blending with validated endpoint controls.

The lowest strength generally presents the greatest content-uniformity challenge.

Blend segregation

Differences in density and particle size between glimepiride and the excipient system can cause segregation during transfer, hopper discharge and tablet compression. A formulation that performs well in a laboratory blender may fail during commercial-scale handling.

Process controls should include blend uniformity, thief sampling strategy, hopper studies, compression-startup testing and hold-time evaluation.

Dissolution and bioequivalence

Glimepiride is practically insoluble in water, making dissolution a key formulation variable. Excipient grade, particle size, wetting behavior, granulation method and lubricant exposure can all affect release.

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. Formulations that use a different excipient system can still be viable, but the developer must control comparative dissolution and meet FDA requirements for inactive ingredients.[2]

Tablet identification

The reference product uses color differentiation between strengths. A generic manufacturer can select another appearance, but the product must satisfy labeling, imprinting, stability and medication-error requirements. Strength-specific color can remain commercially useful in markets where patients or pharmacists rely on visual differentiation.

What patents protect Amaryl and glimepiride?

The original Amaryl composition and glimepiride exclusivity have expired in the United States. Generic glimepiride tablets are commercially available, and the product is not protected by a current U.S. biologic exclusivity framework.

IP or regulatory element	Current commercial relevance
Original glimepiride compound and product patents	Expired or no longer commercially blocking in the U.S.
Amaryl immediate-release tablet	Generic competition established
Formulation patents	No broadly blocking Amaryl formulation position identified from the current conventional product profile
Method-of-use patents	Potentially relevant only if directed to a distinct, enforceable use not covered by the ordinary diabetes indication
Orange Book listing	Must be checked against the current FDA edition and NDA record
Paragraph IV activity	Core market entry occurred historically; current opportunity is primarily post-exclusivity competition

The absence of core exclusivity does not eliminate all patent risk. A later patent could cover a particular fixed-dose combination, modified-release profile, manufacturing process or patient population. Such patents would not necessarily block a conventional immediate-release glimepiride tablet.

What is the Orange Book status of Amaryl?

The FDA Orange Book identifies approved drug products, therapeutic equivalence evaluations and certain listed patent or exclusivity information.[3]

Amaryl's commercial position is consistent with an off-patent small-molecule product:

• glimepiride immediate-release tablets have generic equivalents;
• no reference-product exclusivity currently prevents ordinary ANDA competition;
• patent analysis must distinguish the original Amaryl product from later glimepiride combinations or delivery systems;
• an applicant should review the current Orange Book patent certification requirements before submission.

A Paragraph IV certification is generally relevant when an applicant challenges an unexpired listed patent. For the conventional Amaryl tablet, the principal commercial risk is unlikely to be a fresh Paragraph IV fight over the old product. The more relevant risks are regulatory deficiencies, bioequivalence failure, manufacturing cost and market crowding.

When did Amaryl lose exclusivity?

Amaryl lost meaningful U.S. market exclusivity years ago, and generic glimepiride products are established. The original brand opportunity has therefore shifted from protected pricing to residual brand recognition, supply reliability and physician familiarity.

The exact historical sequence depends on the jurisdiction and the specific patent family. U.S. exclusivity analysis should separate:

1. FDA approval of the original NDA;
2. expiration of compound or product patents;
3. any pediatric or other statutory exclusivity;
4. approval dates for the first ANDAs;
5. current therapeutic-equivalence listings.

The practical conclusion is clear: a new conventional glimepiride tablet is a generic-entry product, not an originator-exclusivity product.

What formulation opportunities exist for glimepiride?

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, older adults and patients with difficulty swallowing conventional tablets. The formulation would require careful control of taste, friability, moisture sensitivity and mouthfeel.

Potential excipients include:

• mannitol for mouthfeel and rapid dissolution;
• crospovidone or sodium starch glycolate for disintegration;
• low-substituted hydroxypropyl cellulose for structure;
• colloidal silicon dioxide for flow;
• sweeteners and flavors for palatability;
• taste-masking polymers or coated glimepiride particles.

The principal commercial question is whether the product can obtain meaningful price or channel differentiation in a mature generic class.

Mini-tablets or sprinkle dosage forms

Mini-tablets could address swallowing difficulties and permit administration with soft food. They would require robust dose-unit control and clear administration instructions. Regulatory complexity rises if the product is marketed for sprinkling, because the manufacturer must demonstrate stability and dose delivery under the proposed use conditions.

Fast-disintegrating conventional tablets

A simpler opportunity is an immediate-release tablet with faster disintegration but without the full complexity of an orally disintegrating dosage form. This can use a conventional excipient platform and may present a lower development burden than a true ODT.

Fixed-dose combinations with metformin

The largest formulation opportunity is a glimepiride-metformin combination. Such products can reduce pill burden and target patients receiving both agents.

Development issues include:

• different dose ratios;
• tablet size;
• metformin's high dose and hygroscopicity;
• dissolution of both actives;
• chemical compatibility;
• packaging and moisture control;
• regulatory requirements for the combination product.

The commercial field is crowded, with multiple glimepiride/metformin products in international markets. A new entrant would need a cost, channel, strength, adherence or geographic advantage.

Modified-release products

A modified-release glimepiride product could attempt to reduce peak-related adverse effects or alter dosing convenience. The commercial rationale is weaker because conventional glimepiride is already administered once daily. A modified-release product would face formulation, clinical and bioequivalence burdens without an obvious strong market need.

How can excipients create commercial differentiation?

Excipient selection can support differentiation in four ways.

Lower manufacturing cost

A generic manufacturer can reduce cost by using broadly available compendial grades, simplifying processing and minimizing specialty excipients. The lowest-cost product is not necessarily the most competitive if it has poor flow or high rejection rates.

Higher process robustness

A co-processed filler-binder or optimized granulation platform may reduce batch variability. This is valuable where low-dose content uniformity is the main risk.

Patient-centric dosage forms

Mannitol-based ODTs, mini-tablets and taste-masked formulations can create a differentiated product, although the reimbursement premium may be limited.

Regional supply resilience

An excipient system based on multiple qualified suppliers can reduce exposure to supply interruptions. This is commercially relevant for high-volume public tenders and markets with limited local manufacturing capacity.

The FDA Inactive Ingredient Database can help developers assess precedent for proposed excipients and routes of administration.[4] A novel excipient or unusual level may require additional safety justification and can extend development timelines.

Which companies are challenging Amaryl commercially?

The main competitive group consists of generic manufacturers rather than companies pursuing originator-style patent challenges.

Competition typically comes from:

• multinational generic manufacturers;
• regional pharmaceutical companies;
• contract manufacturers supplying private-label products;
• manufacturers of glimepiride/metformin combinations;
• low-cost suppliers competing in tender markets.

The competitive advantage is usually determined by manufacturing cost, regulatory approvals, supply continuity, distributor access and combination-product breadth. Patent litigation is less likely to be the central barrier for a conventional glimepiride tablet than for newer diabetes therapies such as GLP-1 receptor agonists, SGLT2 inhibitors or DPP-4 inhibitors.

What FDA regulatory pathway applies to a new glimepiride tablet?

A conventional generic glimepiride tablet would generally proceed through an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The applicant must address:

• pharmaceutical equivalence;
• active ingredient identity and strength;
• dosage form and route;
• quality and manufacturing controls;
• bioequivalence;
• dissolution;
• labeling;
• inactive-ingredient acceptability;
• therapeutic equivalence after approval.

A differentiated ODT, sprinkle product or modified-release formulation may require a more complex regulatory strategy, depending on whether the product remains eligible for the ANDA pathway and whether it differs from the reference product in dosage form, route or release characteristics.

What generic entry risks exist for Amaryl?

The generic-entry risk for conventional Amaryl is high because:

1. the active ingredient is off patent;
2. generic products are established;
3. the dosage form is technically conventional;
4. manufacturing can use common compendial excipients;
5. no biologic interchangeability barrier applies;
6. physician switching costs are low.

The commercial risks for a new entrant are different from the legal risks. They include price erosion, limited formulary differentiation, tender concentration, active-ingredient supply constraints and the cost of maintaining multiple strengths.

A developer can improve its position by launching a full strength range, securing redundant API sources, using a low-variance blend process and pursuing combination products or patient-centric dosage forms.

How strong is the Amaryl patent estate?

The legacy Amaryl patent estate is weak as a current barrier to conventional generic entry. The product is a mature small molecule with established generic substitution.

A new patent estate could be stronger if it covers a technically credible and commercially relevant feature, such as:

• a novel fixed-dose ratio;
• a validated taste-masking system;
• a specific ODT architecture;
• a stability-enhancing packaging and formulation combination;
• a clinically meaningful modified-release profile;
• a manufacturing process that produces a distinct impurity or dissolution profile.

Process patents alone may have limited blocking value if competitors can use an alternative process. Formulation patents are stronger when the claimed excipient range is narrow, difficult to design around and tied to measurable performance.

What is the revenue opportunity for glimepiride products?

Amaryl itself is unlikely to offer the revenue profile of protected diabetes brands. Revenue exposure is concentrated in mature generic volume rather than high unit pricing.

Commercial opportunities include:

Opportunity	Market attractiveness	Principal barrier
Standard 1 mg, 2 mg and 4 mg tablets	Moderate volume, low margin	Price competition
Glimepiride/metformin combinations	Moderate	Crowded market and large tablets
ODT glimepiride	Niche premium potential	Taste masking and limited reimbursement premium
Mini-tablets or sprinkle products	Niche	Administration validation
Emerging-market supply	Moderate to high volume	Tender pricing and registration
Contract manufacturing	Moderate	Quality systems and customer concentration

Brand-specific Amaryl revenue should not be inferred from Sanofi's consolidated diabetes reporting because company disclosures generally do not provide a reliable standalone revenue line for the product. The more defensible commercial assessment is based on product maturity, generic penetration and formulation differentiation.

What manufacturing and IP barriers remain?

Manufacturing barriers are manageable but meaningful. The most important controls involve:

• API particle-size specification;
• low-dose premix preparation;
• blend uniformity;
• lubrication time;
• compression force;
• dissolution release testing;
• moisture protection;
• scale-up transfer;
• supplier qualification.

IP barriers are limited for the standard tablet but can become material for a differentiated product. A freedom-to-operate review should cover current patents on glimepiride combinations, ODT technologies, taste masking, modified release, co-processing and manufacturing methods in each target country.

Geographic coverage also matters. A product may be unblocked in the United States while facing active formulation or combination patents in another jurisdiction. Patent expiry, regulatory approval and therapeutic-equivalence standards must be assessed country by country.

Key Takeaways

• Amaryl contains glimepiride and is a conventional immediate-release tablet.
• The principal excipients are lactose monohydrate, microcrystalline cellulose, povidone, sodium starch glycolate and magnesium stearate.
• The central formulation risk is low-dose content uniformity, especially for the 1 mg strength.
• Core Amaryl exclusivity has expired, and generic competition is established.
• A conventional tablet is a low-barrier, price-sensitive opportunity.
• The strongest differentiation options are glimepiride/metformin combinations, ODTs, mini-tablets and robust low-cost manufacturing.
• Formulation patents may support a new product, but they are unlikely to restore broad exclusivity to the legacy Amaryl tablet.
• FDA pathway selection depends on whether the product is a conventional equivalent or a materially differentiated dosage form.
• Commercial value is more likely to come from scale, supply reliability and geographic access than from premium pricing.

FAQs About Amaryl Excipients and Commercial Strategy

Does Amaryl contain lactose?

Yes. The U.S. Amaryl labeling identifies lactose monohydrate as an inactive ingredient.[1]

Can a glimepiride generic use different excipients from Amaryl?

Yes. A generic can use a different inactive-ingredient system if it meets FDA requirements, remains acceptable for the dosage form and demonstrates pharmaceutical equivalence and bioequivalence.

Is glimepiride suitable for an orally disintegrating tablet?

Yes, technically. The main development issues are taste masking, dose uniformity, mechanical strength, moisture control and proof of comparable drug release.

Are glimepiride and metformin combination products patentable?

A specific combination formulation may be patentable if it meets novelty, inventive-step or non-obviousness and enablement requirements. The existence of glimepiride/metformin products makes broad composition claims more difficult.

Is Amaryl a biologic and does it face biosimilar competition?

No. Amaryl contains the synthetic small molecule glimepiride. It faces generic-drug competition, not biosimilar competition.

References

1. U.S. Food and Drug Administration. (2022). Amaryl (glimepiride) tablets: Prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2015). Generic drug user fee amendments: Bioequivalence studies for immediate-release solid oral dosage forms. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.